Bipolar Disorder (2018) |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Bipolar Disorder or Schizophrenia |
1.38 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 TKT |
Depressed Affect (Nagel 2018) |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP3-508I15.9 |
Intelligence (Savage-Jansen 2018) |
0.78 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RAD51AP2 TKT |
Neuroticism (Nagel 2018) |
1.07 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP3-508I15.9 TKT |
Schizophrenia (2018) |
1.36 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 TKT |
Schizophrenia vs Biploar Disorder |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Worry (Nagel 2018) |
0.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TKT |
Crohns Disease (2017) |
1.51 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 GIGYF1 ZBTB38 |
Irritable Bowel Disease (IBD) |
0.88 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 GIGYF1 |
Reaction Time |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CPNE8 |
Verbal and Numeric Reasoning (VNR) |
1.06 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RAD51AP2 TKT |
Breast Cancer |
1.31 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZBTB38 |
Coronary Artery Disease (CAD) |
1.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Fasting Glucose |
3.83 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS1 FNDC4 |
HDL Cholesterol |
2.10 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS1 |
LDL Cholesterol |
2.20 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS1 FNDC4 |
Schizophrenia (2014) |
1.45 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 TKT |
Triglycerides |
10.31 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
BBS4 FADS1 FNDC4 |
Blood Eosinophil Count |
0.80 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS1 SLC22A17 TRAIP |
Blood Platelet Count |
2.42 |
7 |
5 |
11.1 |
0.60 |
1.5e-01 |
ACTN4 CEP120 FADS1 FNDC4 HCN4 RP3-508I15.9 VSTM2L |
Blood Red Count |
2.14 |
10 |
9 |
20.0 |
0.62 |
5.7e-02 |
BBS4 C6orf170 FADS1 FNDC4 GIGYF1 GJA1 NAA16 TKT TRAIP ZBTB38 |
Blood White Count |
1.59 |
6 |
2 |
4.4 |
0.16 |
7.6e-01 |
ACTN4 C6orf204 CEP120 FADS1 FNDC4 NAA16 |
Heel T-Score |
2.00 |
8 |
7 |
15.6 |
0.25 |
5.1e-01 |
C6orf204 CEP120 FADS1 GIGYF1 GJA1 RP3-508I15.9 TRAIP ZBTB38 |
BMI |
0.77 |
4 |
4 |
8.9 |
0.31 |
6.9e-01 |
BBS4 CEP120 FNDC4 HCN4 |
Height |
4.08 |
17 |
6 |
13.3 |
-0.17 |
5.1e-01 |
ALG10 ARHGEF40 BBS4 CAPN1 CEP120 CMTM5 FADS1 FNDC4 GIGYF1 NEO1 NGDN RP3-508I15.9 SMC6 SPON1 TBC1D32 TKT ZBTB38 |
Waist Hip Ratio (WHR) |
1.81 |
6 |
3 |
6.7 |
-0.34 |
4.5e-01 |
ALG10 REEP2 SLC22A17 TKT TRAIP ZBTB38 |
Systolic Blood Pressure |
1.45 |
7 |
2 |
4.4 |
-0.23 |
6.2e-01 |
CD34 CEP120 FNDC4 HOMEZ NAA16 SLC22A17 TCF21 |
Smoking Status |
0.92 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRAIP |
Allergy or Eczema |
1.26 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 ZBTB38 |
Cardiovascular Disease |
1.32 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
FNDC4 NAA16 TCF21 |
Hypothyroidism (self reported) |
1.29 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 GIGYF1 |
Respiratory disease |
1.12 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS1 GJA1 |
Type 2 Diabetes (T2D) (2018) |
2.29 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 SMC6 TRAIP |
Lung FEV1/FVC ratio |
1.40 |
8 |
1 |
2.2 |
-0.13 |
7.4e-01 |
ACTN4 CEP120 GJA1 RAD51AP2 SLC22A17 SMC6 TCF21 ZBTB38 |
Lung FVC |
1.19 |
7 |
3 |
6.7 |
0.09 |
8.4e-01 |
C6orf204 CAPN1 CD34 CEP120 FADS1 TCF21 ZBTB38 |
Neuroticism |
1.04 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP11-381K20.5 SLC22A17 |
Chronotype (morning person) |
2.12 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ALG10 CPNE8 |
Hair Pigment |
0.64 |
5 |
2 |
4.4 |
0.04 |
9.5e-01 |
FNDC4 GIGYF1 NEO1 REEP2 ZBTB38 |
Tanning |
0.20 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Hand grip strength (left) |
1.51 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ARHGEF40 ZBTB38 |
Number of treatments/medications taken |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Relative age of first facial hair |
1.69 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 ZBTB38 |
Ever used hormone-replacement therapy (HRT) |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP3-508I15.9 |
Systolic blood pressure, automated reading |
1.47 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
HOMEZ RBM23 SLC22A17 |
Angina |
1.88 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
Medication: Metformin |
1.96 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Diabetes (father) |
1.58 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Diabetes (mother) |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 |
Impedance of leg (right) |
1.43 |
4 |
2 |
4.4 |
0.80 |
2.0e-01 |
ARHGEF40 CEP120 FNDC4 VSTM2L |
Leg fat-free mass (left) |
3.02 |
6 |
5 |
11.1 |
-0.33 |
5.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Trunk fat percentage |
1.32 |
4 |
2 |
4.4 |
0.91 |
8.9e-02 |
BBS4 HCN4 TRAIP ZBTB38 |
Hand grip strength (right) |
1.47 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ARHGEF40 GIGYF1 ZBTB38 |
Relative age voice broke |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRAIP |
Heel bone mineral density (BMD) T-score, automated (left) |
1.50 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP3-508I15.9 TRAIP |
Serious illness, injury or assault to yourself |
1.27 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMC6 |
High blood pressure |
0.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Hayfever, allergic rhinitis or eczema |
1.17 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZBTB38 |
Medication: Levothyroxine sodium |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 |
Sitting height |
3.39 |
9 |
5 |
11.1 |
-0.12 |
7.6e-01 |
ARHGEF40 CEP120 CMTM5 FADS1 FNDC4 KIAA1755 NEO1 VSTM2L ZBTB38 |
Body mass index (BMI) |
0.74 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
BBS4 CEP120 FNDC4 |
Impedance of leg (left) |
1.50 |
4 |
3 |
6.7 |
0.81 |
1.9e-01 |
ARHGEF40 CEP120 FNDC4 VSTM2L |
Leg predicted mass (left) |
3.03 |
6 |
5 |
11.1 |
-0.34 |
5.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Trunk fat mass |
1.67 |
4 |
2 |
4.4 |
0.69 |
3.1e-01 |
BBS4 CEP120 TRAIP ZBTB38 |
Waist circumference |
1.42 |
5 |
3 |
6.7 |
0.41 |
4.9e-01 |
BBS4 CEP120 FNDC4 HCN4 ZBTB38 |
Nervous feelings |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FLRT2 |
Frequency of tenseness / restlessness in last 2 weeks |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TKT |
Forced vital capacity (FVC) |
1.73 |
4 |
2 |
4.4 |
-0.20 |
8.0e-01 |
BBS4 CAPN1 CEP120 ZBTB38 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.76 |
4 |
1 |
2.2 |
-0.11 |
8.9e-01 |
ALG10 RP3-508I15.9 TRAIP ZBTB38 |
Ever unenthusiastic/disinterested for a whole week |
1.55 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 |
Heart attack |
1.45 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Allergy |
1.18 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZBTB38 |
Diabetes (self-reported) |
1.85 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Simvastatin |
1.61 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS1 FNDC4 |
Fluid intelligence score |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TKT |
Illnesses of siblings |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMC6 |
Neuroticism score |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC22A17 |
Weight |
2.33 |
4 |
3 |
6.7 |
-0.18 |
8.2e-01 |
CAPN1 CEP120 FNDC4 ZBTB38 |
Impedance of arm (right) |
1.45 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CEP120 FNDC4 REEP2 |
Arm fat percentage (right) |
0.90 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
BBS4 |
Trunk fat-free mass |
3.69 |
5 |
5 |
11.1 |
-0.47 |
4.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Hip circumference |
1.58 |
5 |
4 |
8.9 |
-0.40 |
5.1e-01 |
CAPN1 CEP120 FNDC4 RP3-508I15.9 ZBTB38 |
Alcohol intake versus 10 years previously |
1.93 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Frequency of tiredness / lethargy in last 2 weeks |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRAIP |
Number of live births |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 |
Forced expiratory volume in 1-second (FEV1) |
1.44 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CEP120 ZBTB38 |
Mouth/teeth dental problems: Dentures |
0.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
BBS4 |
Asthma |
1.14 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 GJA1 ZBTB38 |
Medication: Cholesterol lowering |
2.18 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TCF21 |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.65 |
3 |
2 |
4.4 |
-0.83 |
1.7e-01 |
CEP120 GJA1 ZBTB38 |
Impedance of arm (left) |
1.54 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CEP120 FNDC4 REEP2 |
Arm fat mass (right) |
1.19 |
4 |
2 |
4.4 |
0.55 |
4.5e-01 |
BBS4 CEP120 FNDC4 ZBTB38 |
Trunk predicted mass |
3.71 |
5 |
5 |
11.1 |
-0.48 |
4.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Standing height |
3.84 |
7 |
6 |
13.3 |
-0.18 |
7.0e-01 |
ARHGEF40 CAPN1 CEP120 FADS1 FNDC4 RAD51AP2 ZBTB38 |
Seen doctor (GP) for nerves, anxiety, tension or depression |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TKT |
Hair/balding pattern: Pattern 4 |
1.61 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS1 ZBTB38 |
Birth weight of first child |
1.39 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZBTB38 |
Peak expiratory flow (PEF) |
1.14 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
Pulse wave reflection index |
5.46 |
3 |
1 |
2.2 |
-0.99 |
8.4e-03 |
HOMEZ KIAA1755 VSTM2L |
Headache pain in last month |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
BBS4 |
Medication for cholesterol, blood pressure or diabetes |
1.34 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FNDC4 TCF21 |
Gout (self-reported) |
3.43 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 TKT |
Hypothyroidism/myxoedema (self-reported) |
1.19 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 GIGYF1 |
Medication: Amlodipine |
1.16 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CD34 TCF21 |
Birth weight |
1.55 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARHGEF40 CEP120 |
Forced vital capacity (FVC), Best measure |
1.94 |
5 |
2 |
4.4 |
-0.45 |
4.4e-01 |
BBS4 CAPN1 CEP120 SPON1 ZBTB38 |
Body fat percentage |
1.18 |
5 |
1 |
2.2 |
0.96 |
8.1e-03 |
BBS4 HCN4 NEO1 TRAIP ZBTB38 |
Leg fat percentage (right) |
1.09 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
BBS4 HCN4 NEO1 |
Arm fat-free mass (right) |
3.30 |
6 |
4 |
8.9 |
-0.33 |
5.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 |
Qualifications: College or University degree |
0.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NEO1 |
Medication: Blood pressure |
0.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Angina (self-reported) |
1.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
Medication: Allopurinol |
2.80 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Medication: Seretide 50 evohaler |
1.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GJA1 |
Whole body fat mass |
1.44 |
5 |
2 |
4.4 |
0.59 |
3.0e-01 |
BBS4 CEP120 HCN4 TRAIP ZBTB38 |
Leg fat mass (right) |
1.27 |
5 |
2 |
4.4 |
0.52 |
3.7e-01 |
BBS4 CEP120 FNDC4 HCN4 ZBTB38 |
Arm predicted mass (right) |
3.29 |
5 |
5 |
11.1 |
-0.50 |
3.9e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Pulse rate, automated reading |
38.52 |
42 |
41 |
91.1 |
0.99 |
4.5e-38 |
AC005517.3 ACTN4 ALG10 ARHGEF40 BBS4 C6orf170 C6orf204 CAPN1 CD34 CEP120 CMTM5 CPNE8 FADS1 FLRT2 FNDC4 GIGYF1 GJA1 HCN4 HOMEZ KIAA1755 LOC158376 MCM9 NAA16 NEO1 NGDN OSBPL6 RAD51AP2 RBM23 REEP2 RP11-381K20.5 RP3-508I15.9 SLC22A17 SMC6 SPON1 TBC1D32 TCF21 THTPA TKT TRAIP TTN VSTM2L ZBTB38 |
Alcohol intake frequency. |
3.09 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 RP3-508I15.9 |
Comparative height size at age 10 |
3.34 |
6 |
4 |
8.9 |
-0.05 |
9.3e-01 |
ALG10 ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Overall health rating |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP3-508I15.9 |
Hypertension (Self-reported) |
0.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Illnesses of father: Heart disease |
1.25 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Forced expiratory volume in 1-second (FEV1), predicted |
2.49 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZBTB38 |
Whole body fat-free mass |
3.50 |
6 |
5 |
11.1 |
-0.32 |
5.3e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Leg fat-free mass (right) |
3.03 |
6 |
5 |
11.1 |
-0.35 |
5.0e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Arm fat percentage (left) |
0.95 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
BBS4 HCN4 |
Diabetes diagnosed by doctor |
2.25 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 SMC6 |
Mouth/teeth dental problems: Mouth ulcers |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 |
Medication for cholesterol |
1.16 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Asthma (self-reported) |
1.25 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 GJA1 ZBTB38 |
Medication: Aspirin |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.44 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CEP120 GJA1 |
Whole body water mass |
3.51 |
6 |
5 |
11.1 |
-0.33 |
5.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Leg predicted mass (right) |
3.04 |
6 |
5 |
11.1 |
-0.35 |
5.0e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 VSTM2L ZBTB38 |
Arm fat mass (left) |
1.24 |
4 |
3 |
6.7 |
0.53 |
4.7e-01 |
BBS4 CEP120 FNDC4 ZBTB38 |
Number of self-reported non-cancer illnesses |
1.30 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Average weekly champagne plus white wine intake |
1.25 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS1 |
Hearing aid user |
1.41 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CD34 |
High cholesterol (Self-reported) |
2.98 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS1 FNDC4 |
Medication: Bendroflumethiazide |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Medication: Paracetamol |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NEO1 |
Medication: Atorvastatin |
2.24 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Ever smoked |
1.40 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRAIP |
Basal metabolic rate |
3.26 |
5 |
5 |
11.1 |
-0.45 |
4.4e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Leg fat percentage (left) |
1.11 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
BBS4 HCN4 NEO1 |
Arm fat-free mass (left) |
3.32 |
5 |
4 |
8.9 |
-0.47 |
4.2e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |
Ever had prostate specific antigen (PSA) test |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZBTB38 |
Diastolic blood pressure, automated reading |
2.97 |
7 |
2 |
4.4 |
0.96 |
7.9e-04 |
AC005517.3 C6orf204 CEP120 GIGYF1 SPON1 TKT TRAIP |
Vascular/heart problems diagnosed by doctor |
0.89 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TCF21 |
Cholesterol lowering medication |
1.96 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FNDC4 |
Heart attack/myocardial infarction (self-reported) |
1.50 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCF21 |
Impedance of whole body |
1.60 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CEP120 FNDC4 |
Leg fat mass (left) |
1.26 |
5 |
2 |
4.4 |
0.51 |
3.8e-01 |
BBS4 CEP120 FNDC4 HCN4 ZBTB38 |
Arm predicted mass (left) |
3.29 |
5 |
4 |
8.9 |
-0.48 |
4.1e-01 |
ARHGEF40 CAPN1 CEP120 FNDC4 ZBTB38 |